Related Experiment Videos
An analysis of testosterone implants for androgen replacement therapy
D J Handelsman1, M A Mackey, C Howe
1Andrology Unit, Royal Price Alfred Hospital, Sydney NSW, Australia. djh@med.su.oz.au
Clinical Endocrinology
|November 28, 1997
Summary
Fused crystalline testosterone implants are well-tolerated for androgen replacement therapy, with high continuation rates. Extrusion is the most common adverse event, linked to physical activity and implant number.
Area of Science:
- Endocrinology
- Urology
- Androgen Replacement Therapy
Background:
- Testosterone deficiency affects numerous men.
- Androgen replacement therapy (ART) aims to restore testosterone levels.
- Fused crystalline testosterone implants offer a long-term ART option.
Purpose of the Study:
- To evaluate 13 years of experience with fused crystalline testosterone implants for ART.
- To identify usage patterns, continuation rates, and adverse events.
- To determine factors associated with adverse events, including implant extrusion.
Main Methods:
- Retrospective review of prospectively collected data.
- Analysis of patient characteristics and implant procedures.
- Recording and analysis of adverse events during routine follow-up.
Main Results:
- Overall adverse event rate was 11.1%, associated with increased implant numbers and physical activity.
- Implant extrusion (8.5%) was linked to occupational classification and work activity.
- Bleeding (2.3%) associated with more implants, infection (0.6%) more common in thinner men.
- Continuation rate reached 92.7%, increasing with subsequent implants.
Conclusions:
- Testosterone pellet implants demonstrate high clinical acceptability for ART.
- Extrusion is the primary adverse effect, potentially related to mechanical and procedural factors.
- Bleeding and infection are rare; improved delivery methods could enhance this technology.